35 Percent of Eligible Children Receive RSV Prophylaxis With Nirsevimab
TUESDAY, July 22, 2025 -- Despite near universal availability of nirsevimab, only 35 percent of eligible children receive nirsevimab for respiratory syncytial virus (RSV) prophylaxis, according to a study published online July 17 in Pediatrics.
Mahaa M. Ahmed, from the Children's Hospital of Philadelphia, and colleagues examined the distribution of nirsevimab to determine factors associated with receipt of nirsevimab among children younger than 8 months attending one of 32 pediatric primary care practices with almost universal nirsevimab eligibility.
Overall, 35 percent of 7,208 eligible patients received nirsevimab, varying from 20 to 65 percent across practices. The researchers found that the rates of nirsevimab receipt were lower in association with older age (odds ratio, 0.60 for each additional month), Black race (odds ratio, 0.53 versus White infants), very low Child Opportunity Index (COI) scores (odds ratio, 0.70 versus very high COI), and public insurance (0.79 versus private insurance).
"The identification of sociodemographic factors associated with receipt of nirsevimab emphasizes the importance of examining the drivers of these disparities to inform interventions designed to ensure more equitable uptake so that all children are protected from RSV," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Influenza-Linked Hospitalization Rate High in 2024 to 2025 Flu Season
WEDNESDAY, Sept. 17, 2025 -- The cumulative influenza-associated hospitalization rate for the 2024 to 2025 season surpassed all end-of-season rates during the period beginning...
RSV Vaccine Prevents RSV-Linked Hospitalization Among Older Adults Over Two Seasons
FRIDAY, Sept. 12, 2025 -- The respiratory syncytial virus (RSV) vaccine reduces RSV-associated hospitalization among older adults over two seasons, according to a study published...
Infants Without Comorbidities Also at Risk for Severe RSV Infection
THURSDAY, Sept. 11, 2025 -- Comorbidities are seen less often in severe respiratory syncytial virus (RSV) infection in infants younger than 3 months compared with older children...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.